Esperion Logo (primary).png
Esperion to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference
April 06, 2021 08:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 06, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside...
Esperion Logo (primary).png
Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
June 04, 2020 07:00 ET | Esperion Therapeutics, Inc.
– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with...
Esperion Logo (primary).png
Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan
April 20, 2020 07:00 ET | Esperion Therapeutics, Inc.
–  Esperion to Receive $60 Million Upfront Payment  – –  Up to $510 Million in Total Milestones  – –  Substantial Tiered Royalties  – –  Combines Esperion’s Expertise in Lipid Management with...
Esperion Logo (primary).png
Esperion Announces Three Data Presentations of the NEXLETOL™ (bempedoic acid) Tablet and the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC)
March 28, 2020 09:30 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2...
Esperion Logo (primary).png
Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors
March 18, 2020 07:30 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 18, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of...
Esperion Logo (primary).png
Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results
February 27, 2020 07:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided lipid management franchise updates and financial results for the fourth quarter and year ended December 31,...
Esperion Logo (primary).png
Esperion Announces FDA Approval of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
February 26, 2020 17:30 ET | Esperion Therapeutics, Inc.
- NEXLIZET Lowered LDL-C by 38 Percent Compared to Placebo when Added on to Maximally Tolerated Statins -- First Non-Statin, LDL-Cholesterol Lowering Combination Medicine Ever Approved -- Esperion’s...
Esperion Logo (primary).png
Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
February 21, 2020 16:38 ET | Esperion Therapeutics, Inc.
– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. in Nearly 20 Years for Indicated Patients –– NEXLETOL Lowers LDL-Cholesterol with a First-in-Class Mechanism...
Esperion Logo (primary).png
Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
January 31, 2020 07:01 ET | Esperion Therapeutics, Inc.
–  Bempedoic Acid is an Oral, Once-Daily, Non-Statin Medicine that Lowers Bad Cholesterol with a First-in-Class Mechanism ––  Positive CHMP Opinion is Based on the Completed Pivotal Phase 3...